BC Extra | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
BC Extra | Jul 16, 2018
Company News

Management tracks: Cerecor, Sangamo

Neurology play Cerecor Inc. (NASDAQ:CERC) said CFO Mariam Morris is stepping down. She is succeeded by Joe Miller, who was VP of finance at Sucampo Pharmaceuticals Inc., which Mallinckrodt plc (NYSE:MNK) acquired. Additionally, Cerecor hired...
BC Extra | May 21, 2018
Financial News

Sofinnova hires Rothman as venture partner

Sofinnova Partners (Paris, France) hired Martin Rothman as a venture partner. He was CMO and VP of medical affairs at the Medtronic Vascular unit of Medtronic plc (NYSE:MDT)....
BC Extra | May 2, 2018
Company News

United Therapeutics' earnings underperform

United Therapeutics Corp. (NASDAQ:UTHR) fell $7.36 to $104.31 on Wednesday, losing about $320 million in market cap, after reporting 1Q18 earnings below expectations. The biotech said 1Q18 non-GAAP EPS slid 4% to $3.76 for the...
BC Extra | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

Antibody company Immunomedics Inc. (NASDAQ:IMMU) hired Robert Iannone as CMO and head of R&D. He was SVP and head of immuno-oncology, global medicines development at AstraZeneca plc (LSE:AZN; NYSE:AZN). Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX)...
BC Extra | Feb 22, 2018
Company News

United Therapeutics slips on further delays for RemoSynch

United Therapeutics Corp. (NASDAQ:UTHR) fell $12.79 to $122.17, losing $553 million in market cap, after reporting during its 4Q17 earnings call Wednesday that RemoSynch, the implantable drug infusion system for Remodulin treprostinil, will launch "within...
BC Extra | Jan 24, 2018
Company News

Management tracks: Ablynx, Cardiovascular Systems

Nanobody company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) hired Robert Friesen as CSO, effective March 1. He is SVP of science and early development at ProQR Therapeutics N.V. (NASDAQ:PRQR). Medical device company Cardiovascular Systems Inc. (NASDAQ:CSII) said...
BC Week In Review | Jan 5, 2018
Financial News

NexImmune raises $23M series A

NexImmune Inc. (Gaithersburg, Md.) raised $23 million on Jan. 2 in a series A round co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont Capital also participated. The...
BC Extra | Jan 2, 2018
Financial News

NexImmune raises $23M series A

NexImmune Inc. (Gaithersburg, Md.) raised $23 million in a series A round co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont Capital also participated. The immuno-oncology company expects...
BioCentury | Dec 1, 2017
Finance

Semma prepares to deliver

After scaling up its beta cell generation protocol and developing a cell delivery technology, Semma Therapeutics Inc. has raised a $114 million series B round that will enable the company to bring its Type I...
Items per page:
1 - 10 of 303
BC Extra | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
BC Extra | Jul 16, 2018
Company News

Management tracks: Cerecor, Sangamo

Neurology play Cerecor Inc. (NASDAQ:CERC) said CFO Mariam Morris is stepping down. She is succeeded by Joe Miller, who was VP of finance at Sucampo Pharmaceuticals Inc., which Mallinckrodt plc (NYSE:MNK) acquired. Additionally, Cerecor hired...
BC Extra | May 21, 2018
Financial News

Sofinnova hires Rothman as venture partner

Sofinnova Partners (Paris, France) hired Martin Rothman as a venture partner. He was CMO and VP of medical affairs at the Medtronic Vascular unit of Medtronic plc (NYSE:MDT)....
BC Extra | May 2, 2018
Company News

United Therapeutics' earnings underperform

United Therapeutics Corp. (NASDAQ:UTHR) fell $7.36 to $104.31 on Wednesday, losing about $320 million in market cap, after reporting 1Q18 earnings below expectations. The biotech said 1Q18 non-GAAP EPS slid 4% to $3.76 for the...
BC Extra | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

Antibody company Immunomedics Inc. (NASDAQ:IMMU) hired Robert Iannone as CMO and head of R&D. He was SVP and head of immuno-oncology, global medicines development at AstraZeneca plc (LSE:AZN; NYSE:AZN). Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX)...
BC Extra | Feb 22, 2018
Company News

United Therapeutics slips on further delays for RemoSynch

United Therapeutics Corp. (NASDAQ:UTHR) fell $12.79 to $122.17, losing $553 million in market cap, after reporting during its 4Q17 earnings call Wednesday that RemoSynch, the implantable drug infusion system for Remodulin treprostinil, will launch "within...
BC Extra | Jan 24, 2018
Company News

Management tracks: Ablynx, Cardiovascular Systems

Nanobody company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) hired Robert Friesen as CSO, effective March 1. He is SVP of science and early development at ProQR Therapeutics N.V. (NASDAQ:PRQR). Medical device company Cardiovascular Systems Inc. (NASDAQ:CSII) said...
BC Week In Review | Jan 5, 2018
Financial News

NexImmune raises $23M series A

NexImmune Inc. (Gaithersburg, Md.) raised $23 million on Jan. 2 in a series A round co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont Capital also participated. The...
BC Extra | Jan 2, 2018
Financial News

NexImmune raises $23M series A

NexImmune Inc. (Gaithersburg, Md.) raised $23 million in a series A round co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont Capital also participated. The immuno-oncology company expects...
BioCentury | Dec 1, 2017
Finance

Semma prepares to deliver

After scaling up its beta cell generation protocol and developing a cell delivery technology, Semma Therapeutics Inc. has raised a $114 million series B round that will enable the company to bring its Type I...
Items per page:
1 - 10 of 303